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clinical assessment and medical treatment
Ingeborg Barišić1, Mirjana Turkalj2,3,9, Dragan Primorac2,3,4,5,6,7,8
Osteogenesis imperfecta (OI) is a phenotypically and molecularly heterogeneous group of heritable connective tissue disorders 
 characterized by low bone mineral density, recurrent fractures, and bone deformities. Most cases of OI are inherited in an autosomal 
dominant manner and are caused by mutations in the COL1A1 and COL1A2 genes, leading to quantitative or qualitative defects in 
type 1 collagen. More recently, a number of other genes responsible for both recessive and dominant forms of this condition have 
been identifi ed. In this brief review, we discuss current understanding of clinical assessment, follow-up and pharmacological 
 therapies for the treatment of OI. The multidisciplinary surveillance in patients with OI includes periodical hearing and vision testing, 
dental examination, spirometry or body plethysmography, evaluation of heart/valvular function, and neurological and psychologi-
cal assessment. There is a need for regular assessment of bone mineral density (BMD) to evaluate treatment success and disease 
progression, and skeletal radiographs at the time of diagnosis and later as indicated by orthopaedists. Treatment of OI is aimed at 
preventing or controlling the symptoms present in individual patient with the main goals to decrease fracture rate, relieve bone pain, 
and provide suffi  cient bone mass and good muscle strength promoting self-mobility and growth. This requires a multi-disciplinary 
approach, utilizing medical treatment, physical therapy, orthopedic surgery, and nutrition monitoring. Intravenous bisphosphonate 
therapy is the most widely used medical treatment. It has an evident eff ect on BMD of lumbar spine, femoral neck and total hip in 
growing children and can lead to vertebral reshaping after compression fractures, but no signifi cant eff ect on the risk of fractures has 
been observed in adults. Other novel promising therapies include teriparatide, combination therapy with antiresorptive and  anabolic 
drugs, denosumab, transforming growth factor beta, sclerostin and cathepsin K inhibitors, and cell-based therapy, such as bone 
marrow or mesenchymal stem cell transplantation. Gene targeting approaches are still at early stages of investigation.
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INTRODUCTION
Osteogenesis imperfecta (OI), often called „brittle bone dis-
ease“, is an inherited heterogeneous group of connective 
tissue disorders most frequently aff ecting type I collagen, 
which results in increased bone fragility and recurrent frac-
tures (1-3). The majority of OI patients have an autosomal 
dominant heterozygous mutation in the COL1A1 (17q21.31-
q22) or COL1A2 (7q22.1) gene that aff ects one of the two 
α-chains of type I collagen (6-8). Phenotype presentations, 
as well as severity of the disorder in aff ected patients de-
pend on the type of mutation, e.g., mutations in COL1A1/2 
may lead to a decreased amount of normal collagen pre-
senting with mild phenotype (OI type I) or may disrupt the 
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formation of type I collagen triple helix causing more severe 
and even lethal phenotypes (OI type IIA) (4,5,7). After the 
discovery of COL1A1/2 mutations in OI, the four universally 
accepted OI types were used in clinical practice to refl ect 
the degree of OI severity (9). According to severity of clinical 
presentation, OI can by classifi ed into four basic types: mild 
(OI type 1), lethal (OI type 2), severely deforming (OI type 3), 
and moderately deforming (OI type 4) (10). Recently, OI is 
classifi ed into nine major subtypes based on genetic, radio-
graphic and clinical characteristics. The main reason for 
such extended classifi cation is that the mutation in a par-
ticular gene does not necessarily refl ect in a clear clinical 
diagnosis or phenotype expression. This also suggests de-
fects in other connective tissue components, not just colla-
gen structure, which also have an important infl uence on 
full expression of the OI phenotype complexity (7,8). How-
ever, the new OI nomenclature and the Severity Grading 
Scale emphasize the importance of phenotyping in order to 
diagnose, classify and assess OI severity (11). The modifi ed 
classifi cation of OI with specifi c clinical features and inheri-
tance is shown in Table 1 (12). The Severity Grading Scale 
adopted for the POISE (Paediatric Osteogenesis Imperfecta 
Safety and Effi  cacy study) relies on clinical history, frequen-
cy of fractures, bone densitometry, and level of mobility, 
refl ecting also the improved treatment options (conserva-
tive, pharmacological and surgical) (11,13). In fact, careful 
clinical assessment in combination with the specifi c genetic 
and molecular cause is the relevant and important key for 
development and assessment of therapy, but also for pre-
vention of the development of complications in patients 
with OI (14).
CLINICAL ASSESSMENT
Clinical manifestations vary greatly from patient to patient, 
even among the same type or subtype of OI and even with-
in members of the same family. The majority of OI cases 
(possibly 85%-90%) are caused by an autosomal dominant 
mutation in a gene coding for type 1 collagen (types I, II, III 
and IV; see in Table 1). Types V and IX are caused by the 
genes that interfere with collagen production and are in-
herited in a recessive manner (14). These new forms of OI 
are presented with moderate to severe clinical features (pa-
tients have an increased number and frequency of fractures, 
mild to moderate bone deformities, kyphoscoliosis, and 
variable short stature, some are immobile and require 
wheelchair) (9). Generally, severely aff ected patients suff er 
multiple fractures with minimal or no trauma, and infants 
with the worst form of OI die at birth or shortly after be-
cause of respiratory complications (15). Mild forms of OI 
may be manifested only by premature osteoporosis or se-
vere postmenopausal bone mineral loss (16).
Clinical assessment of patients with OI is complex and chal-
lenging due to the heterogeneity both across and within dif-
ferent types. There is no single biomarker or clinical charac-
teristic that can recognize, evaluate or monitor patients with 
OI. In clinical assessment, it is important to establish timely 
diagnosis to initiate treatment as early as possible to prevent 
progression and complications of the disease (17, 18).
The diagnosis is usually easy to establish in patients with 
positive family history, bone fragility, and expressed extra-
skeletal manifestations (7, 15). However, in the absence of 
these manifestations, making diagnosis may be diffi  cult. 
TABLE 1. Clinical features in osteogenesis imperfect (OI) types, adapted and extended classifi cation of OI by Sillence et al. (12)
Type Genetic Bone fragility/ deformity Teeth Sclera Spine Hearing
Cardio-respiratory 
complications Prognosis
IA AD Variable, less severe than 
other types, deformity 
moderate




loss (early twenties 
or thirties)
Usually absent
Possible in patients 
with kyphoscoliosis
Fair
IB AD Normal/na? Dentinogenesis 
imperfecta
NA NA Possible Sbsent NA
II AD Very severe/multiple 
fractures
Unknown Blue NA NA Frequently causing 
death at birth
Perinatal death
III AD Severe/ progressive 







Kyphoscoliosis Possible Possible Wheelchair 
bound, not 
ambulatory
IVA AD Moderate Normal White or 
near-white
Kyphoscoliosis Possible Possible Fair
IVB AD NA Dentinogenesis 
imperfecta
NA NA NA NA NA
V-IX AD or AR 
(VII-IX)
Similar to type IV or type 





in some to NA
Hearing loss 
in some
Possible to severe Wheelchair 
bound to death 
(VII and VIII)
NA = not applicable, AD = autosomal dominant, AR = autosomal recessive
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Extra-skeletal features can be subclinical (e.g., hearing loss) 
(11, 14, 16), nonspecifi c (e.g., dark or bluish sclera in infants), 
or more clearly expressed at certain ages (e.g., dentinogen-
esis imperfecta more pronounced in primary than in per-
manent dentition) (16).
Patients with OI should undergo regular multidisciplinary 
surveillance for potential complications, so that appropriate 
intervention is initiated as soon as possible (18). Optimal 
management of OI in children and later in adults requires a 
multidisciplinary approach involving diff erent paediatric 
subspecialists (e.g., pulmonologist, cardiologist, endocri-
nologist, geneticist), orthopaedic surgeon, endocrinologist, 
rehabilitation specialist, dentist, psychologist, physiothera-
pist, and occupational therapist (19). In the clinical assess-
ment and monitoring of patients with OI, the following is 
recommended:
 – Assessment of bone mineral density (BMD) by dual-ener-
gy absorptiometry (DXA) is the standard and most wide-
ly used method to measure bone density (usually lower 
spine, hips and wrist). If possible, DXA scans should be 
done using the same machine each year to avoid varia-
tions in test results caused by diff erent equipment. BMD 
is related to disease severity (functional outcome, rate of 
fractures, and rate of surgery) and/or initiated pharmaco-
logical therapies (20). Children receiving bisphospho-
nate (BP) treatment should have yearly (or more fre-
quently as clinically indicated) assessment of BMD and 
radiologic assessment of long bones and spine to deter-
mine the eff ect of treatment on vertebral geometry, 
long-bone fractures, and changes in bone mass (21).
 – Bone biopsy has been used as an invasive diagnostic 
procedure and is an important method in the research of 
OI and other metabolic bone diseases. Bone biopsy is 
not a regular diagnostic method or procedure performed 
in regular monitoring of patients with OI. When feasible, 
a biopsy of the iliac bone can identify all types of OI. Bone 
biopsy is invasive, requiring specially trained personnel, 
general anaesthesia, and the child must weigh at least 10 
kg. A bone biopsy may be obtained during orthopaedic 
surgery.
 – Skeletal radiographs should be performed at the time of 
diagnosis and then every 1-2 years (or sooner if clinically 
indicated) in cooperation with orthopaedists (20). Discrep-
ancies in leg length can be caused by fractures or prob-
lems with growth plates. These discrepancies need to be 
evaluated by a gait specialist, most commonly orthopae-
dist, to prevent the child from losing the ability to walk. 
The goals of orthopaedic assessment include fracture care 
and prevention or correction of bone deformities.
 – Hearing test to evaluate conductive and sensorineural 
hearing loss in cooperation with the ENT specialist. Hear-
ing test (formal audiology) is recommended initially at 
nine months of age and then at regular intervals (22, 23).
 – Vision screening every 2-3 years, with referral to an oph-
thalmologist as indicated by clinical fi ndings (24).
 – Spirometry or body plethysmography to monitor for re-
strictive disturbances of ventilation secondary to rib and 
vertebral fractures or spine/chest deformities, every 1-2 
years if clinically indicated, particularly in patients with 
moderate to severe OI. Patients with OI type III or other 
moderate to severe types of OI should have yearly pul-
monary ventilation tests (25).
 – Cardiovascular system involvement in patients with OI 
can occur even without the presence of clinical manifes-
tations. In the assessment of cardiovascular complica-
tions, electrocardiogram and echocardiogram should be 
performed every two years to detect aortic root dilation 
and valvular dysfunction (26). A small number of adults 
with OI have heart valve problems, the most common 
being mitral valve prolapse. Dilation of the aorta may 
also occur but is not common. If the OI patient is sus-
pected to have developed cardiovascular complications 
such as aortic dilatation, it is recommended to perform 
additional diagnostics such as magnetic resonance im-
aging (MRI) of the heart and large blood vessels, and to 
order more frequent follow-up visits (27).
 – Neurologic examination should be part of regular man-
agement of OI patients. Basilar skull deformity could lead 
to basilar invagination, as indicated by symptoms or be-
havioural changes, particularly in patients with type III OI 
or similar phenotype (types VII to IX) (28).
 – Developmental assessment (primary care paediatrician) 
with referral to early intervention specialists for those 
younger than three years and referral to physical and oc-
cupational therapy for those older than three years of 
age (29). A child’s large muscle development in patients 
with OI may be aff ected by fractures, muscle weakness, 
abnormal body size, shape and proportion, misalign-
ment of long bones and joints. Some types of OI are 
characterized by signifi cantly short stature (2, 7). Since OI 
has a signifi cant eff ect on growth (and development) es-
pecially during puberty, it is important to include endo-
crinologist in the multidisciplinary team for clinical as-
sessment of OI patients.
 – Psychological assessment should be performed routine-
ly in all infants with OI and their families within the fi rst 
few months of life, and later on regular basis. The psy-
chologist can identify patients and families likely to be at 
an increased risk of developing psychological diffi  culties 
in order to off er preventive intervention (17, 30, 31).
 – Dietetic assessment is particularly recommended to 
more severely aff ected infants with feeding problems 
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(e.g., weak sucking refl ex, gastroesophageal refl ux, or 
lung aspiration problems) and older children with limit-
ed mobility and poor or unhealthy diet. Dietitian can 
suggest dietary modifi cations and develop nutritional 
care plans to help infants and children develop a healthy 
lifestyle diet that supports optimal bone mass, muscle 
strength, and aiming at avoiding obesity (17, 29).
 – Dental assessment as indicated for dentinogenesis im-
perfecta. Dentinogenesis imperfecta is evident in ap-
proximately 50% of patients with OI and is characterized 
by transparent, discoloured and fragile teeth that frac-
ture easily. Dental abnormalities are usually apparent 
when the fi rst tooth erupts (31). Patients with OI require 
dutiful oral hygiene and frequent follow-up by a paediat-
ric dentist who is familiar with the disorder.
 – Assessment of coagulopathy (bleeding time and coagu-
lation tests) before any surgical procedure should be per-
formed in all patients with OI. The bleeding diathesis as-
sociated with OI related to capillary fragility and abnor-
malities of platelet function results in a signifi cant risk of 
haemorrhage during or after surgery. Large-bone intra-
venous access should be obtained before major surgical 
procedures to allow for rapid administration of fl uid and 
blood products. In addition, nonsteroid anti-infl ammato-
ry drugs should probably be avoided because of their 
antiplatelet eff ects (32).
 – Hyperthermia may occur in patients with OI for unclear 
reasons, but these patients are not at an increased risk of 
malignant hyperthermia (21).
 – Biochemical and hormonal laboratory parameters of 
bone and mineral metabolism such as serum and urine 
calcium, serum phosphorus, alkaline phosphatase (ALP), 
and parathyroid hormone (PTH) are usually normal in pa-
tients with mild type of OI (2,7,16). Some abnormalities 
have been reported, e.g., elevated levels of serum ALP (OI 
type VI) (34), or hypercalciuria, which refl ects the severity 
of bone disease. The children with hypercalciuria were of 
shorter stature and had a greater lifelong fracture rate 
compared with OI children with normal urinary calcium 
excretion (35). Monitoring the levels of vitamin D (mea-
sured as 25-hydroxyvitamin D, 25(OH)D) is also impor-
tant in the management of OI patients. Over the last de-
cade, there has been increasing awareness of the role of 
vitamin D in bone health. Specifi c data suggest that vita-
min D insuffi  ciency was observed in 80% of children with 
osteopenia or osteoporosis (36). Several of published 
data assessing vitamin D status in paediatric OI patients 
demonstrated a positive association between 25(OH) D 
levels and lumbar spine areal bone mineral but no clear 
evidence for association between other markers of bone 
mineralization, bone metabolism or bone mass in chil-
dren with OI (37). OI adults with short stature may require 
less calcium and vitamin D supplements than usually 
prescribed. Supplemental vitamin D intake should not 
exceed 800 IU/day (38).
TREATMENT
Treatment of OI is aimed at preventing or controlling the 
symptoms present in individual patient. The main goals of 
treatment are to decrease fracture rate, relieve bone pain, 
and provide bone mineral mass and muscle strength in or-
der to achieve as long as possible normal self-mobility and 
linear growth. This requires a multidisciplinary approach, 
utilizing pharmacological treatment, physical therapy, or-
thopaedic surgery, and nutrition monitoring. 
Pharmacological treatment
Pharmacological treatment includes primarily analgesics 
and bone-strengthening drugs, such as BPs. Intravenous 
BPs are currently the principal medical treatment of chil-
dren with moderate to severe OI. The mechanism of BP ac-
tivity is based on adhesion to mineralized surfaces and inac-
tivation of osteoclasts, leading to the inhibition of bone re-
sorption and increase of BMD. Although often used, BPs 
only slow the progression of the symptoms and have no 
eff ect on OI pathogenesis.
It is known that BPs increase BMD, height and shape of the 
vertebral column. In addition, some studies have shown 
that the frequency of fractures, and possibly pain, is re-
duced, while muscle strength and mobility are improved 
(13, 39, 40). However, it has been diffi  cult to confi rm all of 
these fi ndings in randomized trials. A systematic study on 
the effi  cacy of treatment with BPs has confi rmed that oral 
and intravenous administration equally increases BMD, but 
it has not been conclusively confi rmed that the number of 
fractures is reduced or that treatment improves clinical sta-
tus, i.e. reduces pain, increases linear growth, or improves 
mobility (21). Additionally, a recent meta-analysis of place-
bo-controlled trials suggests that the eff ects of BPs on frac-
ture prevention are inconclusive (41). These studies point to 
the fact that BMD reduction does not imply per se a reduc-
tion in the number of fractures or improvement in other 
clinical outcomes.
In contrast, some recent studies still confi rm clinical effi  cacy 
of BP administration but only in children. A Swedish study 
showed that pamidronate treatment in children with all 
types of OI increased lumbosacral BMD, decreased fracture 
rate, and improved healing of vertebral compression frac-
tures. Fracture reduction was prompt and maintained dur-
ing treatment, irrespective of age at treatment initiation and 
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collagen I mutation type (42). Long-term intravenous or oral 
BP treatment has positive eff ects on lumbar spine, femoral 
neck and total hip BMD, bone turnover markers and fracture 
risk, with a good safety profi le in children (43, 44), but no 
signifi cant eff ect on the risk of fractures was observed in 
adults (45, 46). These fi ndings are supported by a meta-
analysis of nine randomized controlled trials including 557 
patients, demonstrating that BPs were effi  cacious in reduc-
ing fractures in children, whereas in adults the eff ect of ad-
ministering BPs was equivalent to placebo (47).
While the effi  cacy of BP treatment does not seem to be re-
lated to the genotype of type I collagen in patients with OI 
(48), therapeutic success might also depend on the type of 
OI. Patients with OI type VI who received intravenous BP 
treatment during linear growth (total duration of BP treat-
ment between 1.6 and 13.8 years, median 8.3 years) had an 
increase in lumbar spine areal BMD, a higher fi nal height z-
score, and showed reshaping of vertebral bodies, but major 
problems such as high fracture rates of lower extremities, 
scoliosis, and restricted mobility function persisted in most 
patients (49).
The decision to initiate BP administration is based on the 
severity of clinical manifestations, patient age, and ability to 
manage oral or intravenous administration (50). Diff erent 
treatment protocols are in use. Decision on the type and 
mode of BP administration is made in agreement with the 
parents. Because of the long half-life of BPs and the risk of 
adynamic bone, it is important to use the lowest eff ective 
cumulative dose to improve bone density and vertebral ge-
ometry (51). It is possible to adjust the dose individually, de-
pending on the response to treatment. Duration of treat-
ment, interval between cycles, and dose titration are still 
topics of studies. The maximum benefi t of BPs is seen in the 
fi rst two to four years of treatment, after which it seems that 
there is little further improvement (52). Therefore, a regimen 
in which children are treated with pamidronate for 3 years, 
then followed carefully for fractures, bone density and ver-
tebral geometry over subsequent years is favoured by some 
experts (51). Bone metabolism is suppressed for 2 years af-
ter BP discontinuation. Although bone mass gain continues 
after cessation of treatment, BMD in lumbar spine increases 
less than in healthy individuals (53).
Treatment with BPs still raises concerns. BP anti-absorption 
activity prevents normal remodelling necessary for bone 
restoration. It is unknown whether these changes in bone 
formation can have signifi cant adverse eff ects. There is a 
concern related to the danger of micro-fractures and calcifi -
cation of cartilage, which can contribute to slower healing 
of the fractures and to increased bone brittleness. A study 
investigating structural and mechanical properties of corti-
cal bone samples from children with OI treated with BPs 
showed that the microstructure was impaired. The higher 
porosity and osteocyte lacunar density negatively impacted 
the mechanical properties and made the bone more prone 
to fractures (54). Additionally, atypical fractures have been 
reported in children with OI treated with BPs (55). Although 
there is no clear evidence for slower bone healing after a 
fracture, there is evidence for a signifi cant delay in osteoto-
my recovery after surgical procedures. Treatment is not rec-
ommended for 4-6 months after osteotomy, when x-rays 
show a satisfactory healing process. Delayed osteotomy 
healing occurs less frequently in the past 10 years than in 
the decade before that. It is likely that this is attributable to 
the improvement in both medical and surgical manage-
ment (56).
After discontinuation of BP treatment in children, the new 
bone forming at the bone growth plate is less dense. It is 
believed that the junction between treated bone and new 
bone is prone to stress leading to new fractures. For this rea-
son, some experts recommend maintenance therapy until 
the end of linear growth (57).
Osteonecrosis is often referred to as a complication associ-
ated with BP treatment. This phenomenon was largely ob-
served in elderly patients with cancer who were on BP ther-
apy. To date, however, there have been no cases of osteone-
crosis of the jaw in patients with OI (58).
In a recent systematic review that included randomized 
controlled trials assessing the eff ects of BPs in children with 
OI, the most frequently reported adverse events were gas-
trointestinal complaints, fever, and muscle soreness (59). 
Muscle and bone pain reported by some patients with OI 
are considered important side eff ects that may limit BP use 
in a subset of patients (60). On the other hand, many studies 
report on a signifi cant decrease in bone pain during BP 
treatment (59).
It should be kept in mind that the half-life of BP breakdown 
in bones is at least ten years and that their long-term eff ect 
is unknown, which is especially important in children and in 
women of reproductive age (60).
In conclusion, although BPs are eff ective in treating osteo-
porosis, the benefi t of their use in OI in relation to undesir-
able side eff ects is still questionable. As BPs are currently 
extensively used for long-term treatment of OI, additional 
research is needed to determine the best and safest way of 
their use and to evaluate long-term effi  cacy in reducing 
fractures and improving the patient quality of life.
Teriparatide
The parathyroid hormone is eff ectively applied in post-
menopausal osteoporosis because it has anabolic eff ect on 
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the bone. Clinical trials with teriparatide (PTH 1-34), an ac-
tive part of the endogenous human parathyroid hormone 
(PTH), in adults with OI have shown that teriparatide has 
anabolic eff ect in the mild form of OI. It increases BMD in 
the hip, spine and vertebra, and improves estimated verte-
bral strength (61). However, teriparatide did not lead to a 
signifi cant reduction in the number of fractures, or other 
clinical eff ects. Its use in children is still not recommended 
because there is evidence from experiments that it causes 
osteosarcoma in young rats (57).
Growth hormone
Growth hormone (GH) has anabolic eff ects on bone. It has 
long been considered that GH administration could be of 
benefi t for patients with OI, but it has been shown that GH 
increases bone turnover, which is harmful for OI patients. In 
addition, children with OI present on average with normal 
insulin-like growth factor 1 (IGF-1) and insulin-like growth 
factor-binding protein 3 (IGFBP-3) levels (62). Still, there is 
evidence for the positive eff ect of GH on BMD and on 
growth rate in about half of the treated patients (63). A 
1-year randomized controlled study showed that GH would 
increase the rate of linear growth in a subgroup of patients 
and that it might be eff ective in combination with BP thera-
py, but there was no improvement in fracture rate (64).
Denosumab
Denosumab, a monoclonal antibody to receptor activator of 
nuclear factor kappa-B ligand (RANKL), has emerged as an 
important novel therapy for OI. A 48-week, open-label, pilot 
study of the safety and effi  cacy of denosumab administered 
subcutaneously every 12 weeks in a dose of 1 mg/kg body 
weight in 10 children with OI suggests that denosumab may 
be benefi cial in decreasing bone turnover and increasing 
BMD. No severe side eff ects were noted (65). However, data in 
paediatric patients are limited. At present, there are safety 
concerns related to rebound increase of bone turnover and 
impaired mineral homeostasis that limit the use of denosum-
ab in children (66). Additional studies are needed to deter-
mine if and how these eff ects can be mitigated (67).
Recent medical treatment options
New pharmacological treatments showing promising re-
sults are currently being under investigation. An excellent 
review summarizes diff erent therapeutic options including 
antiresorptive agents, anabolic treatment, and gene- and 
cell-therapy approaches (68).
Transforming growth factor beta (TGF-β) is a protein impor-
tant in bone formation. It is well-known that TGF-β, which is 
produced by osteoblasts, has a capacity to modify bone re-
modelling by coupling the activity of bone resorbing osteo-
clasts with bone forming osteoblasts (69). In studies on 
mice with OI, it has been shown that silencing TGF-β can 
lead to higher bone mass, quality and strength (70). Fresoli-
mumab is an antibody that can silence TGF-β. A study de-
signed to determine if fresolimumab is safe in the treatment 
of OI is currently under way (ClinicalTrials.gov Identifi er: 
NCT03064074).
Sclerostin is a naturally occurring protein encoded by the 
SOST gene and produced almost exclusively by osteocytes. 
It inhibits bone formation by binding to the low-density li-
poprotein receptor related protein 5 and 6 on osteoblasts. 
Sclerostin also leads to down-regulation of phosphate reg-
ulating endopeptidase homologue X-linked (PHEX). PHEX 
degrades peptides that bind to nascent bone mineral and 
inhibit mineral deposition. Therefore, down-regulation of 
PHEX results in decreased bone mineralization (71). Addi-
tionally, sclerostin inhibits canonical wnt signalling path-
way, an important regulator of bone mass that induces os-
teoblastogenesis and bone formation, and suppresses os-
teoclastogenesis and bone resorption (72). Experiments 
with a variety of animal models have shown that inhibition 
of sclerostin results in increased bone formation and re-
duced bone resorption (73). A recent study has shown that 
a combination of sclerostin antibody and zoledronic acid 
treatment outperforms either treatment alone in a mouse 
model of OI (74). The short-term, open-label, phase 2a trial 
aimed to evaluate the pharmacodynamics and safety of 
multiple, escalating infusions of BPS804, a neutralizing, anti-
sclerostin antibody, indicates that BPS804 stimulates bone 
formation, reduces bone resorption, and increases lumbar 
spine BMD in adults with moderate OI (75).
Cathepsin K inhibition results in reduction of the enzymatic 
resorption process of the extracellular matrix by mature os-
teoclasts (76). In comparison with BPs, the eff ect of cathep-
sin inhibitors is transient and reversible (77). However, ca-
thepsin inhibitors have not yet been studied in patients 
with OI. Additional concerns are raised because it was found 
that treatment might be associated with an increased risk of 
cerebrovascular accidents (78).
Cell-based therapy, such as bone marrow or mesenchymal 
stem cell transplantation, has also been investigated. Trans-
plantation of human foetal mesenchymal stem cells has 
been proposed as skeletal anabolic therapy to enhance 
bone formation. Intraperitoneal injection of human amni-
otic mesenchymal stem cells into a mouse model of OI re-
duced fracture susceptibility, increased bone strength, im-
proved bone quality and micro-architecture, normalized 
bone remodelling, and reduced TNFα and TGFβ signalling. 
Donor cells engrafted into bones, diff erentiated into osteo-
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blasts and promoted endogenous osteogenesis and matu-
ration of resident osteoblasts (79).
Other therapies including gene targeting approaches are 
under evaluation. A promising option could be gene silenc-
ing through RNA interference (80).
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S A Ž E T A K
Osteogenesis imperfecta: klinička procjena i liječenje
Ingeborg Barišić, Mirjana Turkalj, Dragan Primorac
Osteogenesis imperfecta (OI) je fenotipski i molekularno heterogena skupina nasljednih bolesti veziva obilježena smanjenom gusto-
ćom kostiju, čestim lomovima i deformacijama. Većina OI-a nasljeđuje se autosomno dominantno i uzrokovana je mutacijama u 
genima COL1A1 i COL1A2, što dovodi do kvantitativnog ili kvalitativnog defekta kolagena tip 1. U posljednje vrijeme otkriven je veći 
broj gena koji su odgovorni za recesivne i dominantne oblike ove bolesti. U ovom kratkom pregledu razmatramo suvremeni pristup 
kliničkoj dijagnostici i praćenju te farmakološkom liječenju OI-a. Multidisciplinsko praćenje bolesnika uključuje povremeno testiranje 
sluha i vida, stomatološke preglede, spirometriju ili pletizmografi ju, evaluaciju funkcije srca/valvula, neurološke i psihološke kontrole. 
Potrebno je redovito pratiti vrijednosti gustoće kostiju (BMD) kako bi se utvrdio uspjeh liječenja i progresija bolesti, a nužne su i 
 rengenske slike kostiju kod postavljanja dijagnoze i kasnije prema indikaciji ortopeda.
Svrha liječenja je i da spriječi ili suzbije simptome prisutne kod pojedinog bolesnika, a glavni ciljevi su smanjiti broj lomova, suzbiti 
bol, poboljšati koštanu masu i mišićnu snagu te osigurati samostalnu pokretnost i rast. To zahtijeva multidisciplinski pristup u liječe-
nju lijekovima, fi zikalnom terapijom, kiruškim ortopedskim zahvatima i odgovarajućom prehranom. Intravenska primjena bisfosfo-
nata je najšire primjenjivan oblik medikamentoznog liječenja. Ona ima očit učinak na BMD slabinske kralježnice, vrata bedrene kosti 
i kukova djece u rastu, te može dovesti do preoblikovanja kralježaka nakon kompresijskih fraktura, ali nema značajnijeg učinka na 
rizik pojave lomova kod odraslih osoba. Druge nove obećavajuće terapije uključuju teriparatid, liječenje kombinacijom antiresorptiv-
nih i anaboličih lijekova, denosumab, inhibiciju TGF-β (eng. transforming growth factor beta), sklerostina i kathepsina K te staničnu 
terapiju, poput transplantacije koštane srži ili mezenimalnih stanica. Genska terapija je još u ranim stadijima ispitivanja.
Ključne riječi:  djeca, frakture, osteogenesis imperfecta, mineralna gustoća kostiju, bisfosfonatei, denosumab, teriparatid, 
mezenhmalne matične stanice, transformirajući čimbenik rasta beta, protutijelo na sklerostin, hormon rasta 
